现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
8期
1933-1936
,共4页
岳丽娟%侯新丽%薛辉%薛玲%高翔%沈勇%袁亮%张晶晶%朱宏财
嶽麗娟%侯新麗%薛輝%薛玲%高翔%瀋勇%袁亮%張晶晶%硃宏財
악려연%후신려%설휘%설령%고상%침용%원량%장정정%주굉재
卵巢癌%腹腔积液%热灌注化疗%静脉化疗
卵巢癌%腹腔積液%熱灌註化療%靜脈化療
란소암%복강적액%열관주화료%정맥화료
ovarian cancer%ascites%intraperitoneal hyperthermal chemotherapy%intravenous chemotherapy
目的:探讨晚期卵巢癌行腹腔热灌注联合静脉化疗的临床疗效及不良反应。方法:2008年12月-2012年12月收治的100例晚期卵巢癌并大、中量腹腔积液患者采用信封法随机分为治疗组和对照组。治疗组60例,行腹腔热灌注联合静脉化疗;对照组40例,行单纯的静脉化疗。治疗组采用顺铂腹腔热灌注联合紫杉醇静脉化疗,对照组采用紫杉醇联合顺铂静脉化疗,观察两组的腹水控制率及不良反应。结果:治疗组的腹水控制率为78.3%,对照组为42.5%,差异具有统计学意义(P ﹤0.01)。两组的不良反应比较无统计学差异(P ﹥0.05)。结论:腹腔热灌注联合静脉化疗可有效的控制卵巢癌患者恶性腹腔积液,不良反应能够耐受。
目的:探討晚期卵巢癌行腹腔熱灌註聯閤靜脈化療的臨床療效及不良反應。方法:2008年12月-2012年12月收治的100例晚期卵巢癌併大、中量腹腔積液患者採用信封法隨機分為治療組和對照組。治療組60例,行腹腔熱灌註聯閤靜脈化療;對照組40例,行單純的靜脈化療。治療組採用順鉑腹腔熱灌註聯閤紫杉醇靜脈化療,對照組採用紫杉醇聯閤順鉑靜脈化療,觀察兩組的腹水控製率及不良反應。結果:治療組的腹水控製率為78.3%,對照組為42.5%,差異具有統計學意義(P ﹤0.01)。兩組的不良反應比較無統計學差異(P ﹥0.05)。結論:腹腔熱灌註聯閤靜脈化療可有效的控製卵巢癌患者噁性腹腔積液,不良反應能夠耐受。
목적:탐토만기란소암행복강열관주연합정맥화료적림상료효급불량반응。방법:2008년12월-2012년12월수치적100례만기란소암병대、중량복강적액환자채용신봉법수궤분위치료조화대조조。치료조60례,행복강열관주연합정맥화료;대조조40례,행단순적정맥화료。치료조채용순박복강열관주연합자삼순정맥화료,대조조채용자삼순연합순박정맥화료,관찰량조적복수공제솔급불량반응。결과:치료조적복수공제솔위78.3%,대조조위42.5%,차이구유통계학의의(P ﹤0.01)。량조적불량반응비교무통계학차이(P ﹥0.05)。결론:복강열관주연합정맥화료가유효적공제란소암환자악성복강적액,불량반응능구내수。
Intraperitoneal hyperthermic chemotherapy(IHCT)has been used in the treatment of ovari-an cancer,to determine the efficacy of IHCT combined with intravenous chemotherapy in the treatment of advanced o-varian cancer. Methods:From 2008 to 2012,100 patients with advanced ovarian cancer were enrolled in a prospective nonrandomized study to undergo IHCT combined with intravenous chemotherapy. There were 60 cases in the treatment group,receiving intraperitoneal hyperthermal chemotherapy with DDP and intravenous chemotherapy with PTX. There were 40 cases in the control group,receiving intravenous chemotherapy with PTX and DDP. The ascites control rate and the main side effects were observed in the two groups. Results:The ascites control rate was 78. 3% in the treat-ment group and 42. 5% in the control group,with a significant difference between the two groups(P ﹤ 0. 01). The rates of the main side effects in the two groups were not significantly different(P ﹥ 0. 05). Conclusion:The effect of IHCT combined with intravenous chemotherapy on advanced ovarian carcinoma is better than that of intravenous chemotherapy alone and is a well - tolerated,feasible,and promising method of treatment in advanced ovarian cancer.